Celularity Inc. Capital Expenditures
Celularity Inc. (CELU) reported Capital Expenditures of $161.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-04-30
- Celularity Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $91.00K, a 84.31% decline year-over-year.
- Celularity Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Celularity Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-06-30 was $31.00K, a 0.00% change year-over-year.
- Celularity Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-03-31 was $39.00K, a 81.34% decline year-over-year.
- Celularity Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $161.00K, a 84.64% decline from fiscal 2023.
- Celularity Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $1.05M, a 79.98% decline from fiscal 2022.
- Celularity Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $5.24M, a 15.59% decline from fiscal 2021.
- Celularity Inc. payments to acquire property, plant, and equipment for fiscal 2021 was $6.20M, a 77.71% decline from fiscal 2020.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 9 month as first filed | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $91.00K derived: sum of 2 quarters · filed 2026-04-30 | $122.00K derived: sum of 3 quarters · filed 2026-04-30 | $161.00K 10-K · filed 2026-04-30 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $31.00K derived: sum of 2 quarters · filed 2025-11-14 | $70.00K 10-Q · filed 2025-11-14 | $105.00K 10-Q · filed 2024-12-06 | $650.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $70.00K 10-Q · filed 2025-08-29 | $650.00K derived: sum of 3 quarters · filed 2025-08-29 | $878.00K derived: sum of 4 quarters · filed 2025-08-29 | |
| 2024-03-31 | $39.00K 10-Q · filed 2025-08-29 | $619.00K derived: sum of 2 quarters · filed 2025-08-29 | $847.00K derived: sum of 3 quarters · filed 2025-08-29 | $878.00K derived: sum of 4 quarters · filed 2025-08-29 | |
| 2023-12-31 | $580.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $808.00K derived: sum of 2 quarters · filed 2025-05-08 | $839.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.05M 10-K · filed 2025-05-08 | |
| 2023-09-30 | $228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $259.00K derived: sum of 2 quarters · filed 2024-12-06 | $468.00K 10-Q · filed 2024-12-06 | $1.25M derived: sum of 4 quarters · filed 2024-12-06 | |
| 2023-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $240.00K 10-Q · filed 2024-11-07 | $1.02M derived: sum of 3 quarters · filed 2024-11-07 | $2.58M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-03-31 | $209.00K 10-Q · filed 2024-10-16 | $988.00K derived: sum of 2 quarters · filed 2024-10-16 | $2.55M derived: sum of 3 quarters · filed 2024-10-16 | $3.99M derived: sum of 4 quarters · filed 2024-10-16 | |
| 2022-12-31 | $779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $2.34M derived: sum of 2 quarters · filed 2024-07-30 | $3.78M derived: sum of 3 quarters · filed 2024-07-30 | $5.24M 10-K · filed 2024-07-30 | |
| 2022-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | $3.00M derived: sum of 2 quarters · filed 2024-01-03 | $4.46M 10-Q · filed 2024-01-03 | $6.76M derived: sum of 4 quarters · filed 2024-01-03 | |
| 2022-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $2.89M 10-Q · filed 2023-08-14 | $5.20M derived: sum of 3 quarters · filed 2023-08-14 | $6.31M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $1.45M 10-Q · filed 2023-05-22 | $3.76M derived: sum of 2 quarters · filed 2023-05-22 | $4.87M derived: sum of 3 quarters · filed 2023-05-22 | $6.18M derived: sum of 4 quarters · filed 2023-05-22 | |
| 2021-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.42M derived: sum of 2 quarters · filed 2023-03-31 | $4.72M derived: sum of 3 quarters · filed 2023-03-31 | $6.20M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.42M derived: sum of 2 quarters · filed 2022-11-10 | $3.90M 10-Q · filed 2022-11-10 | $13.27M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.79M 10-Q · filed 2022-08-09 | $12.16M derived: sum of 3 quarters · filed 2022-08-09 | ||
| 2021-03-31 | $1.48M 10-Q · filed 2022-05-16 | $10.85M derived: sum of 2 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $9.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $27.83M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $18.46M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |